the Dax rose moderately on Wednesday and hovered around 16,000 points. The latest data on price developments in the US reassured investors a little after some market participants feared an even more pronounced surge in prices. At the close of trading, the leading German index was 0.4 percent higher at 16,010 points. In addition to the corona pandemic, the prospect of rising interest rates is currently a negative factor for stocks. The fact that inflation in the USA reached its highest level in almost 40 years in December and has now increased to 7.0 percent was expected and has therefore already been factored into the exchange rates.
Among the individual values in the Dax, the shares of RWE as the top favorite attracted interest with a plus of two percent. Börsenbrief author Hans Bernecker highlighted the wind power project in Spain announced the day before, including the high electricity prices as a support. Teamviewer caused a sensation with a price increase of 15 percent. The software company’s quarterly results exceeded expectations, wrote DZ Bank analyst Armin Kremser. “On the other hand, we do not see the positive development as a real surprise, since the management board had made the new outlook extremely conservative after the profit warning.”
In view of negative news from Dutch competitor Philips, the shares of Siemens Healthineers fell by 0.6 percent. Philips shares themselves collapsed on the Amsterdam Stock Exchange by 15 percent after the medical technology group had announced a 40 percent decline in earnings for the final quarter. Missing electronic components and a mass recall of ventilators made Philips a problem. On Wall Street, the Dow Jones ended the trading session a little higher at 36,290 points. Encouraging test results for the coronavirus vaccine gave the Ocugen titles a boost. The shares of the pharmaceutical company rose at times by 11.5 percent. According to development partner Bharat Biotech, a booster vaccination with the serum neutralizes both the Delta and the Omikron variants. The vaccine has emergency approval from the World Health Organization.